Kaken Pharmaceutical Co., Ltd. (KKPCF)

Market Cap	1.04B +0.5%
Revenue (ttm)	482.58M -18.9%
Net Income	-24.44M
EPS	-0.64
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	1.24 (4.79%)
Ex-Dividend Date	Mar 30, 2026

Volume	200
Average Volume	429
Open	26.00
Previous Close	28.12
Day's Range	26.00 - 26.00
52-Week Range	23.65 - 28.96
Beta	0.06
RSI	45.80
Earnings Date	Feb 6, 2026

About Kaken Pharmaceutical

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surger...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1917
• Employees: 1,126
• Stock Exchange: OTCMKTS
• Ticker Symbol: KKPCF

Financial Performance

In fiscal year 2025, Kaken Pharmaceutical's revenue was 94.04 billion, an increase of 30.52% compared to the previous year's 72.04 billion. Earnings were 13.95 billion, an increase of 73.77%.

Financial numbers in JPY